Limits...
Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.

Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D, Yu J - Cancer Sci. (2014)

Bottom Line: Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05).Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026).It can act as a worse prognostic factor for LARC patients.

View Article: PubMed Central - PubMed

Affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) rates in relation to human epidermal growth factor receptor-2 (HER-2) status. (a) HER-2 positivity in rectal cancers correlate with a shorter DFS curves (P = 0.015). (b) HER-2 positivity in rectal cancers correlate with a shorter OS curves (P = 0.026).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317932&req=5

fig03: Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) rates in relation to human epidermal growth factor receptor-2 (HER-2) status. (a) HER-2 positivity in rectal cancers correlate with a shorter DFS curves (P = 0.015). (b) HER-2 positivity in rectal cancers correlate with a shorter OS curves (P = 0.026).

Mentions: Node status (N), HER-2 status, and depth of invasion (T) were found to be significantly correlated with 5-year DFS and OS, as listed in Table 4. The 5-year DFS of 22 patients with HER-2 positive status was significantly shorter than that of 97 patients with HER-2 negative status (P = 0.015) (Fig. 3a). In the total study population, HER-2-negative patients had significantly better OS as compared with HER-2-positive patients (P = 0.026) (Fig. 3b). Compared with the 5-FU/capecitabine group, the patients in the 5-FU/capecitabine and oxaliplatin group had longer DFS and OS, but the difference was not statistically significant (P = 0.213 and P = 0.346).


Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.

Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D, Yu J - Cancer Sci. (2014)

Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) rates in relation to human epidermal growth factor receptor-2 (HER-2) status. (a) HER-2 positivity in rectal cancers correlate with a shorter DFS curves (P = 0.015). (b) HER-2 positivity in rectal cancers correlate with a shorter OS curves (P = 0.026).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317932&req=5

fig03: Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) rates in relation to human epidermal growth factor receptor-2 (HER-2) status. (a) HER-2 positivity in rectal cancers correlate with a shorter DFS curves (P = 0.015). (b) HER-2 positivity in rectal cancers correlate with a shorter OS curves (P = 0.026).
Mentions: Node status (N), HER-2 status, and depth of invasion (T) were found to be significantly correlated with 5-year DFS and OS, as listed in Table 4. The 5-year DFS of 22 patients with HER-2 positive status was significantly shorter than that of 97 patients with HER-2 negative status (P = 0.015) (Fig. 3a). In the total study population, HER-2-negative patients had significantly better OS as compared with HER-2-positive patients (P = 0.026) (Fig. 3b). Compared with the 5-FU/capecitabine group, the patients in the 5-FU/capecitabine and oxaliplatin group had longer DFS and OS, but the difference was not statistically significant (P = 0.213 and P = 0.346).

Bottom Line: Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05).Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026).It can act as a worse prognostic factor for LARC patients.

View Article: PubMed Central - PubMed

Affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.

Show MeSH
Related in: MedlinePlus